Larry Charleston1, Suad Khalil2, William B Young3. 1. Department of Neurology, University of Michigan, 1914 Taubman Center, 1500 E. Medical Center Dr. SPC 5316, Ann Arbor, MI, 48109-5316, USA. larrycha@med.umich.edu. 2. Department of Neurology and Ophthalmology, Michigan State University College of Human Medicine, East Lansing, MI, USA. 3. Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
Abstract
PURPOSE OF REVIEW: To review carnitine's role in migraine and headache, present a case of a patient with intractable chronic migraine refractory to medications but exquisitely responsive to mitochondrial cofactors with a particularly prompt response to L-carnitine supplementation with dose response, and suggest scenarios where L-carnitine could be considered for prophylactic treatment in migraine and intractable headache with migraine features. RECENT FINDINGS: Multiple treatments modalities are used to treat migraine, including nutraceutical therapies. Mitochondrial supplements are often used to treat migraine, based on controlled trials. One of the nutraceutical therapies used in neurological and non-neurological conditions is L-carnitine. A few studies have examined the effect of carnitine in patients with migraine. We present a case of a patient with chronic migraine-like headaches found to have carnitine deficiency whose headaches greatly improved with carnitine supplementation. This case suggests that secondary carnitine deficiency may cause chronic migraine. Energy deficiency states occur with migraine, and replenishment of energy substrates has demonstrated some improvement in migraine. Recent studies suggest that L-carnitine with other mitochondrial cofactors may be migraine preventives. The exact link between carnitine and migraine is unknown. Perhaps carnitine deficiency should be in the differential for refractory migraine. Supplementation with L-carnitine merits exploration as a nutraceutical treatment of chronic migraine. Our case suggests that there may be a dose-dependent response to L-carnitine.
PURPOSE OF REVIEW: To review carnitine's role in migraine and headache, present a case of a patient with intractable chronic migraine refractory to medications but exquisitely responsive to mitochondrial cofactors with a particularly prompt response to L-carnitine supplementation with dose response, and suggest scenarios where L-carnitine could be considered for prophylactic treatment in migraine and intractable headache with migraine features. RECENT FINDINGS: Multiple treatments modalities are used to treat migraine, including nutraceutical therapies. Mitochondrial supplements are often used to treat migraine, based on controlled trials. One of the nutraceutical therapies used in neurological and non-neurological conditions is L-carnitine. A few studies have examined the effect of carnitine in patients with migraine. We present a case of a patient with chronic migraine-like headaches found to have carnitine deficiency whose headaches greatly improved with carnitine supplementation. This case suggests that secondary carnitine deficiency may cause chronic migraine. Energy deficiency states occur with migraine, and replenishment of energy substrates has demonstrated some improvement in migraine. Recent studies suggest that L-carnitine with other mitochondrial cofactors may be migraine preventives. The exact link between carnitine and migraine is unknown. Perhaps carnitine deficiency should be in the differential for refractory migraine. Supplementation with L-carnitine merits exploration as a nutraceutical treatment of chronic migraine. Our case suggests that there may be a dose-dependent response to L-carnitine.
Authors: Lisa A Schimmenti; Eric A Crombez; Bernd C Schwahn; Bryce A Heese; Timothy C Wood; Richard J Schroer; Kristi Bentler; Stephen Cederbaum; Kiki Sarafoglou; Mark McCann; Piero Rinaldo; Dietrich Matern; Cristina Amat di San Filippo; Marzia Pasquali; Susan A Berry; Nicola Longo Journal: Mol Genet Metab Date: 2006-11-28 Impact factor: 4.797
Authors: S Vijay; A Patterson; S Olpin; M J Henderson; S Clark; C Day; G Savill; J H Walter Journal: J Inherit Metab Dis Date: 2006-07-23 Impact factor: 4.982
Authors: Ayman W El-Hattab; Fang-Yuan Li; Joseph Shen; Berkley R Powell; Erawati V Bawle; Darius J Adams; Erica Wahl; Joyce A Kobori; Brett Graham; Fernando Scaglia; Lee-Jun Wong Journal: Genet Med Date: 2010-01 Impact factor: 8.822